Ahead of Rare Disease Day on 28 February, we've published our first ever quality standard on rare diseases, and the first to have been developed in partnership with an external organisation.
A new type of tablet specifically designed to prevent migraine is transforming lives across England, with the number of people being prescribed these medicines more than tripling in just one year.
For the first time, NICE has recommended a medicine that effectively treats the underlying cause of devastating skin condition vitiligo
New guidance means millions of people will get access to medicines that protect the heart and kidneys, while NHS savings of £560 million from using generic dapagliflozin can be reinvested elsewhere in NHS care.
Read our explainer on biosimilars and generics and the potential benefits they can offer.
As Sam Roberts prepared to hand over the baton as chief executive, she reflected on her time at NICE and looked to the next chapter for the organisation. She also reflected on our 2025 highlights and achievements in delivering our transformation plan and our commitments in the 10 Year Plan.
How a collaborative taskforce is helping increase the uptake of biosimilars within the health and care sector.
Understand why we're prioritising key topic areas for evaluation and what it means for innovators
